Immunohistochemical biomarkers in gastric cancer research and management

International Journal of Surgical Oncology

Volumn 2012, Issue , 2012, Pages

  Lastraioli, Elena ^a   Raffaella Romoli, Maria ^a   Arcangeli, Annarosa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84866175124     PISSN: 20901402     EISSN: 20901410     Source Type: Journal    
DOI: 10.1155/2012/868645     Document Type: Review

References (97)

1. Bertuccio P., Chatenoud L., Levi F., Praud D., Ferlay J., Negri E., Malvezzi M., La Vecchia C., Recent patterns in gastric cancer: a global overview. International Journal of Cancer 2009 125 3 666 673 2-s2.0-67650073366 10.1002/ijc.24290
2. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010. CA Cancer Journal for Clinicians 2010 60 5 277 300 2-s2.0-77955635233 10.3322/caac.20073
3. Chen J., Bu X. L., Wang Q. Y., Hu P. J., Chen M. H., Decreasing seroprevalence of Helicobacter pylori infection during 19932003 in Guangzhou, southern China. Helicobacter 2007 12 2 164 169 2-s2.0-33847061164 10.1111/j.1523-5378.2007.00487.x
4. Kawakami E., Machado R. S., Ogata S. K., Langner M., Decrease in prevalence of Helicobacter pylori infection during a 10-year period in Brazilian children. Arquivos de Gastroenterologia 2008 45 2 147 151 2-s2.0-48249092048 10.1590/S0004-28032008000200011
5. Tkachenko M. A., Zhannat N. Z., Erman L. V., Blashenkova E. L., Isachenko S. V., Isachenko O. B., Graham D. Y., Malaty H. M., Dramatic changes in the prevalence of Helicobacter pylori infection during childhood: a 10-year follow-up study in Russia. Journal of Pediatric Gastroenterology and Nutrition 2007 45 4 428 432 2-s2.0-37349072458 10.1097/MPG.0b013e318064589f (Pubitemid 350307160)
6. Lauren P., The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. Acta Pathologica et Microbiologica Scandinavica 1965 64 31 49 2-s2.0-12644292106
7. Correa P., Human gastric carcinogenesis: a multistep and multifactorial processFirst American Cancer Society Award lecture on cancer epidemiology and prevention. Cancer Research 1992 52 24 6735 6740 2-s2.0-0027065034 (Pubitemid 23006271)
8. Carneiro F., Huntsman D. G., Smyrk T. C., Owen D. A., Seruca R., Pharoah P., Caldas C., Sobrinho-Simões M., Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. Journal of Pathology 2004 203 2 681 687 2-s2.0-2642556280 10.1002/path.1564 (Pubitemid 38714105)
9. Leung W. K., Sung J. J. Y., Review article: intestinal metaplasia and gastric carcinogenesis. Alimentary Pharmacology and Therapeutics 2002 16 7 1209 1216 2-s2.0-0036024189 10.1046/j.1365-2036.2002.01300.x
10. Mayer B., Johnson J. P., Leitl F., Jauch K. W., Heiss M. M., Schildberg F. W., Birchmeier W., Funke I., E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Research 1993 53 7 1690 1695 2-s2.0-0027522546 (Pubitemid 23113253)
11. Machado J. C., Carneiro F., Beck S., Rossi S., Lopes J., Taveira-Gomes A., Cardoso-Oliveira M., E-cadherin expression is correlated with the isolated cell/diffuse histotype and with features of biological aggressiveness of gastric carcinoma. International Journal of Surgical Pathology 1998 6 3 135 144 2-s2.0-0031872156 (Pubitemid 28357194)
12. Bremm A., Walch A., Fuchs M., Mages J., Duyster J., Keller G., Hermannstädter C., Becker K. F., Rauser S., Langer R., Von Weyhern C. H., Höfler H., Luber B., Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations. Cancer Research 2008 68 3 707 714 2-s2.0-38849160093 10.1158/0008-5472.CAN-07-1588 (Pubitemid 351206746)
13. Teruya-Feldstein J., The immunohistochemistry laboratory looking at molecules and preparing for tomorrow. Archives of Pathology and Laboratory Medicine 2010 134 11 1659 1665 2-s2.0-78249251787
14. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M. R., Carotenuto A., De Feo G., Caponigro F., Salomon D. S., Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006 366 1 2 16 2-s2.0-32044464123 10.1016/j.gene.2005.10.018 (Pubitemid 43199589)
15. Fornaro L., Lucchesi M., Caparello C., Vasile E., Caponi S., Ginocchi L., Masi G., Falcone A., Anti-HER agents in gastric cancer: from bench to bedside. Nature Reviews Gastroenterology and Hepatology 2011 8 7 369 383 2-s2.0-79960084377 10.1038/nrgastro.2011.81
16. Ménard S., Tagliabue E., Campiglio M., Pupa S. M., Role of HER2 gene overexpression in breast carcinoma. Journal of Cellular Physiology 2000 182 2 150 162 10.1002/(SICI)1097-4652(200002)182:2150::AID-JCP3>3.0.CO;2-E (Pubitemid 30022667)
17. Sorkin A., Goh L. K., Endocytosis and intracellular trafficking of ErbBs. Experimental Cell Research 2008 314 17 3093 3106 2-s2.0-54849372300 10.1016/S0014-4827(08)00404-7
18. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. F., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244 4905 707 712 2-s2.0-0024337144 (Pubitemid 19147683)
19. Giuffrè G., Ieni A., Barresi V., Caruso R. A., Tuccari G., HER2 status in unusual histological variants of gastric adenocarcinomas. Journal of Clinical Pathology 2012 65 3 237 241 10.1136/jclinpath-2011-200345
20. Zhang X. L., Yang Y. S., Xu D. P., Qu J. H., Guo M. Z., Gong Y., Huang J., Comparative study on overexpression of Her2/Neu and Her3 in gastric cancer. World Journal of Surgery 2009 33 10 2112 2118 2-s2.0-70349327606 10.1007/s00268-009-0142-z
21. Gravalos C., Jimeno A., HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology 2008 19 9 1523 1529 2-s2.0-50849123421 10.1093/annonc/mdn169
22. Park D. I., Yun J. W., Park J. H., Oh S. J., Kim H. J., Cho Y. K., Sohn C. I., Jeon W. K., Kim B. I., Yoo C. H., Son B. H., Cho E. Y., Chae S. W., Kim E.-J., Sohn J. H., Ryu S. H., Sepulveda A. R., HER-2/neu amplification is an independent prognostic factor in gastric cancer. Digestive Diseases and Sciences 2006 51 8 1371 1379 10.1007/s10620-005-9057-1 (Pubitemid 44315804)
23. García I., Vizoso F., Martín A., Sanz L., Abdel-Lah O., Raigoso P., García-Muñiz J. L., Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Annals of Surgical Oncology 2003 10 3 234 241 2-s2.0-0037795412 10.1245/ASO.2003.05.010 (Pubitemid 40486955)
24. Van Cutsem E., Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Journal of Clinical Oncology 2009 27 18s
25. Li G.-C., Zhang Z., Ma X.-J., Gu W.-L., Wang Y.-N., Li J., Are biomarkers correlated with recurrence patterns in patients with resectable gastric adenocarcinoma. Molecular Biology Reports 2012 39 1 399 405 10.1007/s11033-011- 0751-0
26. Barros-Silva J. D., Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. British Journal of Cancer 2009 100 3 487 493 2-s2.0-59649084142 10.1038/sj.bjc.6604885
27. Tanner M., Hollmén M., Junttila T. T., Kapanen A. I., Tommola S., Soini Y., Helin H., Salo J., Joensuu H., Sihvo E., Elenius K., Isola J., Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II α gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Annals of Oncology 2005 16 2 273 278 2-s2.0-20044372721 10.1093/annonc/mdi064 (Pubitemid 40309309)
28. Zhao Z.-Q., Yang S., Lu H.-S., Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Molecular Medicine Reports 2012 5 2 415 419 10.3892/mmr.2011.649
29. Osinsky S., Bubnovskaya L., Ganusevich I., Kovelskaya A., Gumenyuk L., Olijnichenko G., Merentsev S., Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clinical and Translational Oncology 2011 13 2 133 138 2-s2.0-79958010073 10.1007/s12094-011-0630-0
30. Wang X., Cao W., Mo M., Wang W., Wu H., Wang J., VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer. Journal of Surgical Oncology 2010 102 4 325 330 2-s2.0-77956580659 10.1002/jso.21644
31. Zhou Y., Clinicapathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumor Biology 2010 31 549 558
32. Chen C. N., Hsieh F. J., Cheng Y. M., Cheng W. F., Su Y. N., Chang K. J., Lee P. H., The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Letters 2004 213 1 73 82 2-s2.0-4344620032 10.1016/j.canlet.2004.05.020 (Pubitemid 39118536)
33. Schimanski C. C., Schlaegel F., Jordan M., Moehler M., Sgourakis G., Drescher D. G., Galle P. R., Lang H., Gockel I., VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. World Journal of Surgery 2011 35 5 1010 1016 2-s2.0-79955686652 10.1007/s00268-011-1041-7
34. Ohtsu A., Shah M. A., Van Cutsem E., Rha S. Y., Sawaki A., Park S. R., Lim H. Y., Yamada Y., Wu J., Langer B., Starnawski M., Kang Y.-K., Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 2011 29 30 3968 3976 10.1200/JCO.2011.36.2236
35. Ding X. W., Yang W. B., Gao S., Wang W., Li Z., Hu W. M., Li J. J., Luo H. S., Prognostic significance of hERG1 expression in gastric cancer. Digestive Diseases and Sciences 2010 55 4 1004 1010 2-s2.0-77950364723 10.1007/s10620-009-0834-0
36. Soon M.-S., Hsu L.-S., Chen C.-J., Chu P.-Y., Liou J.-H., Lin S.-H., Hsu J.-D., Yeh K.-T., Expression of Kruppel-like factor 5 in gastric cancer and its clinical correlation in Taiwan. Virchows Archiv 2011 459 2 161 166 10.1007/s00428-011-1111-0
37. Kwak M. K., Lee H.-J., Hur K., Park D. J., Lee H. S., Kim W. H., Lee K. U., Choe K. J., Guilford P., Yang H.-K., Expression of Krüppel-like factor 5 in human gastric carcinomas. Journal of Cancer Research and Clinical Oncology 2008 134 2 163 167 10.1007/s00432-007-0265-2 (Pubitemid 350234060)
38. Kato Y., Yashiro M., Noda S., Kashiwagi S., Matsuoka J., Fuyuhiro Y., Doi Y., Hirakawa K., Expression of a hypoxia-associated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma. Digestion 2010 82 4 246 251 2-s2.0-77953941961 10.1159/000297208
39. Demirag G. G., Sullu Y., Gurgenyatagi D., Okumus N. O., Yucel I., Expression of plakophilins (PKP1, PKP2, and PKP3) in gastric cancers. Diagnostic Pathology 2011 6 1, article 1 2-s2.0-78650668359 10.1186/1746-1596-6-1
40. Sudo T., Mimori K., Nishida N., Kogo R., Iwaya T., Tanaka F., Shibata K., Fujita H., Shirouzu K., Mori M., Histone deacetylase 1 expression in gastric cancer. Oncology Reports 2011 26 4 777 782 2-s2.0-79960790220 10.3892/or.2011.1361
41. Mutze K., Langer R., Becker K., Ott K., Novotny A., Luber B., Hapfelmeier A., Göttlicher M., Höfler H., Keller G., Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Annals of Surgical Oncology 2010 17 12 3336 3343 2-s2.0-78650990943 10.1245/s10434-010-1182-1
42. Weichert W., Röske A., Gekeler V., Beckers T., Ebert M. P., Pross M., Dietel M., Denkert C., Röcken C., Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. The Lancet Oncology 2008 9 2 139 148 2-s2.0-38549157208 10.1016/S1470-2045(08)70004-4
43. Xu L., Li X., Chu E. S., Zhao G., Go M. Y., Tao Q., Jin H., Zeng Z., Sung J. J., Yu J., Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. GUT 2012 61 7 977 985
44. Lu X., Cheng C., Zhu S., Yang Y., Zheng L., Wang G., Shu X., Wu K., Liu K., Tong Q., SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncology Reports 2010 24 4 981 987 2-s2.0-77957360771 10.3892/or-00000945
45. Cheng C., Lu X., Wang G., Zheng L., Shu X., Zhu S., Liu K., Wu K., Tong Q., Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. Acta Pathologica, Microbiologica et Immunologica Scandinavica 2010 118 11 855 863 2-s2.0-78149248888 10.1111/j.1600-0463.2010. 02673.x
46. Ananiev J., Relation between transforming growth factor-b1 expression, its receptor and clinicopathological factors and survival in HER2-negative gastric cancers. Wiener Klinische Wochenschrift 2011 123 668 673
47. Graziano F., Mandolesi A., Ruzzo A., Bearzi I., Testa E., Arduini F., Silva R., Muretto P., Mari D., Berardi R., Scartozzi M., Lai V., Cascinu S., Magnani M., Predictive and prognostic role of E-cadherin protein expression in patients with advanced gastric carcinomas treated with palliative chemotherapy. Tumor Biology 2004 25 3 106 110 2-s2.0-4644289742 10.1159/000079141 (Pubitemid 39274278)
48. Graziano F., Arduini F., Ruzzo A., Bearzi I., Humar B., More H., Silva R., Muretto P., Guilford P., Testa E., Mari D., Magnani M., Cascinu S., Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clinical Cancer Research 2004 10 8 2784 2789 2-s2.0-11144357007 10.1158/1078-0432.CCR-03-0320 (Pubitemid 38509156)
49. Zhou Y. N., Xu C. P., Han B., Li M., Qiao L., Fang D. C., Yang J. M., Expression of E-cadherin and β -catenin in gastric carcinoma and its correlation with the clinicopathological features and patient survival. World Journal of Gastroenterology 2002 8 6 987 993 2-s2.0-0036900195 (Pubitemid 35446407)
50. Joo Y. E., Park C. S., Kim H. S., Choi S. K., Rew J. S., Kim S. J., Prognostic significance of E-cadherin/catenin complex expression in gastric cancer. Journal of Korean Medical Science 2000 15 6 655 666 2-s2.0-0034573767
51. Shino Y., Watanabe A., Yamada Y., Tanase M., Yamada T., Matsuda M., Yamashita J., Tatsumi M., Miwa T., Nakano H., Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas. Cancer 1995 76 11 2193 2201 10.1002/1097-0142(19951201)76:112193::AID- CNCR2820761104>3.0.CO;2-2
52. Gabbert H. E., Mueller W., Schneiders A., Meier S., Moll R., Birchmeier W., Hommel G., Prognostic value of E-cadherin expression in 413 gastric carcinomas. International Journal of Cancer 1996 69 3 184 189 10.1002/(SICI)1097-0215(19960621)69:3184::AID-IJC6>3.0.CO;2-W (Pubitemid 26233296)
53. Chen H. C., Chu R. Y., Hsu P. N., Hsu P. I., Lu J. Y., Lai K. H., Tseng H. H., Chou N. H., Huang M. S., Tseng C. J., Hsiao M., Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. Cancer Letters 2003 201 1 97 106 2-s2.0-0142122339 10.1016/j.canlet.2003.07.007 (Pubitemid 37298002)
54. Yuan W., Chean Z., Wu S., Ge J., Chang S., Wang X., Chen J., Chen Z., Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathology and Oncology Research 2009 15 3 473 478 2-s2.0-73449147672 10.1007/s12253-008-9132-y
55. Shun C. T., Wu M. S., Lin J. T., Wang H. P., Houng R. L., Lee W. J., Wang T. H., Chuang S. M., An immunohistochemical study of E-cadherin expression with correlations to clinicopathologioal features in gastric cancer. Hepato-Gastroenterology 1998 45 22 944 949 2-s2.0-0031692570
56. Gou H. F., Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphoangiogenesis and prognostic implications. Journal of Experimental & Clinical Cancer Research 2011 30 14
57. Nakao T., Kurita N., Komatsu M., Yoshikawa K., Iwata T., Utsunomiya T., Shimada M., Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. International Journal of Clinical Oncology 2011 16 2 145 152 2-s2.0-79959832634 10.1007/s10147-010-0147-5
58. Jeong S. H., Han J. H., Kim J. H., Ahn M. S., Hwang Y. H., Lee H. W., Kang S. Y., Park J. S., Choi J. H., Lee K. J., Sheen S. S., Lim H. Y., Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Digestive Diseases and Sciences 2011 56 1 131 138 2-s2.0-79151474708 10.1007/s10620-010-1280-8
59. Liu X., Cai H., Huang H., Long Z., Shi Y., Wang Y., The prognostic significance of apoptosis-related biological markers in chinese gastric cancer patients. PLoS ONE 2011 6 12 e29670 10.1371/journal.pone.0029670
60. Holbro T., Civenni G., Hynes N. E., The ErbB receptors and their role in cancer progression. Experimental Cell Research 2003 284 1 99 110 2-s2.0-0037429725 10.1016/S0014-4827(02)00099-X (Pubitemid 36331969)
61. Tan M., Yu D., Molecular mechanisms of ErbB2-mediated breast cancer chemoresistance. Advances in Experimental Medicine and Biology 2007 608 119 129 2-s2.0-38449108764 10.1007/978-0-387-74039-39
62. Uchino S., Tsuda H., Maruyama K., Kinoshita T., Sasako M., Saito T., Kobayashi M., Hirohashi S., Overexpression of c-erbB-2 protein in gastric cancer: its correlation with long-term survival of patients. Cancer 1993 72 11 3179 3184 10.1002/1097-0142(19931201)72:113179::AID-CNCR2820721108>3.0.CO;2-# (Pubitemid 23356757)
63. Nakajima M., Sawada H., Yamada Y., Watanabe A., Tatsumi M., Yamashita J., Matsuda M., Sakaguchi T., Hirao T., Nakano H., The prognostic significance of amplification and overexpression of c- met and c-erb B-2 in human gastric carcinomas. Cancer 1999 85 9 1894 1902 10.1002/(SICI)1097-0142(19990501)85: 91894::AID-CNCR3>3.0.CO;2-J (Pubitemid 29202761)
64. Allgayer H., Babic R., Gruetzner K. U., Tarabichi A., Schildberg F. W., Heiss M. M., c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. Journal of Clinical Oncology 2000 18 11 2201 2209 2-s2.0-0034118639 (Pubitemid 30350211)
65. Ross J. S., Mulcahy M., HER2 testing in gastric/gastroesophageal junction adenocarcinomas: unique features of a familiar test. Gastrointestinal Cancer Research 2011 4 2 62 66
66. Rüschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., Chenard M. P., Penault-Llorca F., Nagelmeier I., Schlake W., Höfler H., Kreipe H. H., HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Archiv 2010 457 3 299 307 2-s2.0-77956895978 10.1007/s00428-010-0952-2
67. Hofmann M., Stoss O., Shi D., Büttner R., Van De Vijver M., Kim W., Ochiai A., Rüschoff J., Henkel T., Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008 52 7 797 805 2-s2.0-44249092320 10.1111/j.1365-2559.2008.03028.x (Pubitemid 351724903)
68. Bang Y. J., Van Cutsem E., Feyereislova A., Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 2010 376 687 697 2-s2.0-77958099652 10.1016/S0140-6736(10)61918-6
69. Tafe L. J., Janjigian Y. Y., Zaidinski M., Hedvat C. V., Hameed M. R., Tang L. H., Hicks J. B., Shah M. A., Barbashina V., Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization. Archives of Pathology and Laboratory Medicine 2011 135 11 1460 1465 10.5858/arpa.2010-0541- OA
70. Park Y. S., Hwang H. S., Park H. J., Ryu M.-H., Chang H.-M., Yook J. H., Kim B. S., Jang S. J., Kang Y.-K., Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Human Pathology 2012 43 3 413 422 10.1016/j.humpath.2011.05.019
71. Osborne C. K., Neven P., Dirix L. Y., Mackey J. R., Robert J., Underhill C., Schiff R., Gutierrez C., Migliaccio I., Anagnostou V. K., Rimm D. L., Magill P., Sellers M., Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clinical Cancer Research 2011 17 5 1147 1159 2-s2.0-79952259688 10.1158/1078-0432.CCR-10-1869
72. Baselga J., Albanell J., Ruiz A., Lluch A., Gascón P., Guillém V., González S., Sauleda S., Marimón I., Tabernero J. M., Koehler M. T., Rojo F., Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. Journal of Clinical Oncology 2005 23 23 5323 5333 2-s2.0-23944464495 10.1200/JCO.2005.08.326 (Pubitemid 46206986)
73. Baselga J., Swain S. M., Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer 2009 9 7 463 475 2-s2.0-67649472398 10.1038/nrc2656
74. Frogne T., Benjaminsen R. V., Sonne-Hansen K., Sorensen B. S., Nexo E., Laenkholm A. V., Rasmussen L. M., Riese D. J., De Cremoux P., Stenvang J., Lykkesfeldt A. E., Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Research and Treatment 2009 114 2 263 275 2-s2.0-59449093537 10.1007/s10549-008-0011-8
75. Ferrara N., Vascular endothelial growth factor. European Journal of Cancer Part A 1996 32 14 2413 2422 2-s2.0-0030500444 10.1016/S0959-8049(96) 00387-5 (Pubitemid 27080779)
76. Ulyatt C., Walker J., Ponnambalam S., Hypoxia differentially regulates VEGFR1 and VEGFR2 levels and alters intracellular signaling and cell migration in endothelial cells. Biochemical and Biophysical Research Communications 2011 404 3 774 779 2-s2.0-78751625796 10.1016/j.bbrc.2010.12.057
77. Kondo K., Kaneko T., Baba M., Konno H., VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer. Biological and Pharmaceutical Bulletin 2007 30 4 633 637 2-s2.0-34147172414 10.1248/bpb.30.633 (Pubitemid 46570975)
78. Iordache S., Saftoiu A., Georgescu C. V., Ramboiu S., Gheonea D. I., Filip M., Schenker M., Ciurea T., Vascular endothelial growth factor expression and microvessel densitytwo useful tools for the assessment of prognosis and survival in gastric cancer patients. Journal of Gastrointestinal and Liver Diseases 2010 19 2 135 139 2-s2.0-77954667439
79. Aurello P., Bellagamba R., Del Monte S. R., D'Angelo F., Nigri G., Cicchini C., Ravaioli M., Ramacciato G., Apoptosis and microvessel density in gastric cancer: correlation with tumor stage and prognosis. American Surgeon 2009 75 12 1183 1188 2-s2.0-73449140794
80. Maeda K., Kang S.-M., Onoda N., Ogawa M., Kato Y., Sawada T., Chung K. H.-Y.-S., Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer 1999 86 4 566 571 10.1002/(SICI)1097-0142(19990815)86:4566:: AID-CNCR4>3.0.CO;2-1 (Pubitemid 29379401)
81. Boku N., Ohtsu A., Nagashima F., Shirao K., Koizumi W., Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP. Japanese Journal of Clinical Oncology 2007 37 7 509 514 2-s2.0-34548349319 10.1093/jjco/hym057 (Pubitemid 47336808)
82. Morals Cabral J. H., Lee A., Cohen S. L., Chait B. T., Li M., Mackinnon R., Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell 1998 95 5 649 655 2-s2.0-0032567106 (Pubitemid 28544126)
83. Sanguinetti M. C., Tristani-Firouzi M., hERG potassium channels and cardiac arrhythmia. Nature 2006 440 7083 463 469 2-s2.0-33645317063 10.1038/nature04710
84. Masi A., Becchetti A., Restano-Cassulini R., Polvani S., Hofmann G., Buccoliero A. M., Paglierani M., Pollo B., Taddei G. L., Gallina P., Di Lorenzo N., Franceschetti S., Wanke E., Arcangeli A., hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. British Journal of Cancer 2005 93 7 781 792 2-s2.0-27144531556 10.1038/sj.bjc.6602775 (Pubitemid 41486438)
85. Arcangeli A., Expression and role of hERG channels in cancer cells. Novartis Foundation Symposium 2005 266 225 232 2-s2.0-23844547384
86. + channels in cell proliferation and apoptosis. Cell Death and Disease 2011 2 8 e193 10.1038/cddis.2011.77
87. Arcangeli A., Becchetti A., Complex functional interaction between integrin receptors and ion channels. Trends in Cell Biology 2006 16 12 631 639 2-s2.0-33751334377 10.1016/j.tcb.2006.10.003 (Pubitemid 44809885)
88. Bianchi L., Wible B., Arcangeli A., Taglialatela M., Morra F., Castaldo P., Crociani O., Rosati B., Faravelli L., Olivotto M., Wanke E., herg encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Research 1998 58 4 815 822 2-s2.0-18844467600 (Pubitemid 28099497)
89. Cherubini A., Taddei G. L., Crociani O., Paglierani M., Buccoliero A. M., Fontana L., Noci I., Borri P., Borrani E., Giachi M., Becchetti A., Rosati B., Wanke E., Olivotto M., Arcangeli A., HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. British Journal of Cancer 2000 83 12 1722 1729 2-s2.0-17744393426 10.1054/bjoc.2000.1497 (Pubitemid 32001720)
90. Pillozzi S., Brizzi M. F., Bernabei P. A., Bartolozzi B., Caporale R., Basile V., Boddi V., Pegoraro L., Becchetti A., Arcangeli A., VEGFR-1 (FLT-1), β 1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 2007 110 4 1238 1250 2-s2.0-34548036519 10.1182/blood-2006-02-003772 (Pubitemid 47281422)
91. Lastraioli E., Bencini L., Bianchini E., Romoli M. R., Crociani O., Giommoni E., Messerini L., Gasperoni S., Moretti R., di Costanzo F., Boni L., Arcangeli A., hERG1 channels and Glut-1 as independent prognostic indicators of worse outcome in stage I and II colorectal cancer: a pilot study. Translational Oncology 2012 5 2 105 112 10.1593/tlo.11250
92. Lastraioli E., Guasti L., Crociani O., Polvani S., Hofmann G., Witchel H., Bencini L., Calistri M., Messerini L., Scatizzi M., Moretti R., Wanke E., Olivotto M., Mugnai G., Arcangeli A., herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Research 2004 64 2 606 611 2-s2.0-9144274941 10.1158/0008-5472.CAN-03- 2360 (Pubitemid 38120900)
93. Lastraioli E., Taddei A., Messerini L., Comin C. E., Festini M., Giannelli M., Tomezzoli A., Paglierani M., Mugnai G., De Manzoni G., Bechi P., Arcangeli A., hERG1 channels in human esophagus: evidence for their aberrant expression in the malignant progression of Barrett's esophagus. Journal of Cellular Physiology 2006 209 2 398 404 2-s2.0-33749252189 10.1002/jcp.20748 (Pubitemid 44484630)
94. Fontana L., D'Amico M., Crociani O., Biagiotti T., Solazzo M., Rosati B., Arcangeli A., Wanke E., Olivotto M., Long-term modulation of HERG channel gating in hypoxia. Biochemical and Biophysical Research Communications 2001 286 5 857 862 2-s2.0-0034811350 10.1006/bbrc.2001.5464 (Pubitemid 32924851)
95. Shao X. D., Wu K. C., Hao Z. M., Hong L., Zhang J., Fan D. M., The potent inhibitory effects of cisapride, a specific blocker for human ether-a-go-go-related gene (HERG) channel, on gastric cancer cells. Cancer Biology and Therapy 2005 4 3 295 301 2-s2.0-25144490098 (Pubitemid 41351289)
96. Lastraioli E., hERG1 channels are overexpressed in human gastric cancer and their activity regulates cell proliferation: a novel prognostic and therapeutic target? Proceedings of the 6th IGCC 2005 Yokohama, Japan 151 154
97. Shao X. D., Wu K. C., Guo X. Z., Xie M. J., Zhang J., Fan D. M., Expression and significance of HERG protein in gastric cancer. Cancer Biology and Therapy 2008 7 1 45 50 2-s2.0-42549114399 (Pubitemid 351590451)